Gene therapy for misfolding protein diseases of the central nervous system

Neurotherapeutics. 2013 Jul;10(3):498-510. doi: 10.1007/s13311-013-0191-8.


Protein aggregation as a result of misfolding is a common theme underlying neurodegenerative diseases. Accordingly, most recent studies aim to prevent protein misfolding and/or aggregation as a strategy to treat these pathologies. For instance, state-of-the-art approaches, such as silencing protein overexpression by means of RNA interference, are being tested with positive outcomes in preclinical models of animals overexpressing the corresponding protein. Therapies designed to treat central nervous system diseases should provide accurate delivery of the therapeutic agent and long-term or chronic expression by means of a nontoxic delivery vehicle. After several years of technical advances and optimization, gene therapy emerges as a promising approach able to fulfill those requirements. In this review we will summarize the latest improvements achieved in gene therapy for central nervous system diseases associated with protein misfolding (e.g., amyotrophic lateral sclerosis, Alzheimer's, Parkinson's, Huntington's, and prion diseases), as well as the most recent approaches in this field to treat these pathologies.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Central Nervous System Diseases* / complications
  • Central Nervous System Diseases* / genetics
  • Central Nervous System Diseases* / therapy
  • Genetic Therapy / methods*
  • Humans
  • Proteostasis Deficiencies* / complications
  • Proteostasis Deficiencies* / genetics
  • Proteostasis Deficiencies* / therapy